​

Bicara Therapeutics (BCAX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

BCAX Stock Forecast

Bicara Therapeutics (BCAX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $32.86, with a high of $42.00 and a low of $20.00. This represents a 94.55% increase from the last price of $16.89.

$15 $21 $27 $33 $39 $45 High: $42 Avg: $32.86 Low: $20 Last Closed Price: $16.89

BCAX Stock Rating

Bicara Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (66.67%), 3 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 3 6 0 Strong Sell Sell Hold Buy Strong Buy

BCAX Price Target Upside V Benchmarks

TypeNameUpside
StockBicara Therapeutics94.55%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1713
Avg Price Target$41.00$32.43$29.54
Last Closing Price$16.89$16.89$16.89
Upside/Downside142.75%92.01%74.90%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 263101--14
Sep, 263103--16
Aug, 26393--15
Jul, 26393--15
Jun, 26393--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 20, 2026Sean LaamanMorgan Stanley$41.00$17.47134.69%142.75%
Aug 18, 2026BMO Capital$35.00$24.9240.45%107.22%
Aug 12, 2026Wedbush$33.00$23.7638.89%95.38%
Aug 12, 2026BTIG$39.00$23.7664.14%130.91%
Aug 12, 2026Joseph CatanzaroMizuho Securities$20.00$23.76-15.82%18.41%
Aug 12, 2026Goldman Sachs$20.00$23.76-15.82%18.41%
Aug 11, 2026Judah FrommerMorgan Stanley$39.00$23.7664.14%130.91%
May 12, 2026Morgan Stanley$37.00$22.3865.33%119.06%
May 12, 2026Goldman Sachs$18.00$22.92-21.47%6.57%
May 11, 2026Guggenheim$42.00$22.5886.01%148.67%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 20, 2026Morgan StanleyOverweightOverweighthold
Sep 22, 2026HSBCEqual-Weightdowngrade
Sep 10, 2026Cantor FitzgeraldOverweightOverweighthold
Aug 21, 2026CitigroupMarket OutperformMarket Outperformhold
Aug 18, 2026BMO CapitalOutperforminitialise
Aug 12, 2026WedbushOutperformOutperformhold
Aug 12, 2026BTIGBuyBuyhold
Aug 12, 2026Goldman SachsNeutralNeutralhold
Aug 11, 2026Morgan StanleyOverweightOverweighthold
May 27, 2026Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-0.40---
Avg Forecast$-2.59$-1.78$-2.61$-2.98
High Forecast$-1.38$-1.42$-2.54$-2.45
Low Forecast$-3.85$-2.50$-2.75$-3.35
Surprise %-84.56%---

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported----
Avg Forecast----
High Forecast----
Low Forecast----
Surprise %----

Net Income Forecast

$-200M $-170M $-140M $-110M $-80M $-50M Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-68.00M---
Avg Forecast$-135.35M$-92.49M$-140.06M$-150.11M
High Forecast$-71.43M$-73.50M$-131.47M$-126.81M
Low Forecast$-199.28M$-129.40M$-142.34M$-173.40M
Surprise %-49.77%---

BCAX Forecast FAQ

Is Bicara Therapeutics stock a buy?

Bicara Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bicara Therapeutics is a favorable investment for most analysts.

What is Bicara Therapeutics's price target?

Bicara Therapeutics's price target, set by 9 Wall Street analysts, averages $32.86 over the next 12 months. The price target range spans from $20 at the low end to $42 at the high end, suggesting a potential 94.55% change from the previous closing price of $16.89.

How does Bicara Therapeutics stock forecast compare to its benchmarks?

Bicara Therapeutics's stock forecast shows a 94.55% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Bicara Therapeutics over the past three months?

  • October 2026: 21.43% Strong Buy, 71.43% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 18.75% Strong Buy, 62.50% Buy, 18.75% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Bicara Therapeutics’s EPS forecast?

Bicara Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.78, marking a 345.00% increase from the reported $-0.4 in 2024. Estimates for the following years are $-2.61 in 2026, and $-2.98 in 2027.

What is Bicara Therapeutics’s revenue forecast?

Bicara Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, and $0 for 2027.

What is Bicara Therapeutics’s net income forecast?

Bicara Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-92.493M, representing an 36.03% increase from the reported $-67.995M in 2024. Projections indicate $-140M in 2026, and $-150M in 2027.